Abstract:There has been little recent success in identifying novel analgesic drug targets and discovering better therapeutics for treating neuropathic pain. Existing analgesic drugs have significant safety, efficacy, tolerability and addiction concerns limiting their use. Recent studies have identified a critical ligand‐gated ion channel on peripheral sensory nerve fiber endings, transient receptor potential ankyrin 1 (TRPA1), as a promising novel analgesic target for treating neuropathic pain. TRPA1 is a validated analgesic target based upon TRPA1 knockout studies in established pain models, pharmacological studies with TRPA1 antagonists and human medical genetic data. Peripherally acting TRPA1 antagonists may provide a novel, safer and more effective option for treating neuropathic pain than existing analgesics. Utilizing a rational drug discovery approach, we have discovered a novel structural class of small molecule, reversible TRPA1 antagonists with excellent drug‐like features using a human TRPA1 fluorescence‐based intracellular calcium assay. Five potent antagonists, ALGX‐2513, ALGX‐2541, ALGX‐2563, ALGX‐2561 and ALGX‐2542, inhibited FFA agonist‐mediated responses with IC 50 s ranging from 23–65nM and were found to be highly selective (>100X) in assays for numerous related TRP channels. ALGX‐2437 and ALGX‐2513 inhibited AITC‐mediated TRPA1 calcium responses in isolated mouse dorsal root ganglion (DRG) neurons, confirming target engagement. In rat PK studies, dosing of ALGX‐2437 and ALGX‐2460 (30 mg/kg) produced robust in vivo drug exposure, achieving high C max values (5–10X IC 50 ) with t max values of 2 hr and t 1/2 values between 3–5 hrs. The analgesic effects of compounds in this series were evaluated in the spinal nerve ligation model (SNL) of neuropathic pain. A single dose (10–50mg/kg) of ALGX‐2437 showed dose‐dependent reversal (EC 50 = 25mg/kg) of mechanical hyperalgesia in the SNL pain model with a maximal possible efficacy (%MPE) of 79% at 2 hr post‐dosing (p<0.0001). Analysis of brain and blood levels showed low brain penetrance of the drug at all dose levels. No adverse behavioral effects, including impairment of rotarod performance, were observed at all doses. In addition, ALGX‐2460, ALGX‐2465 (30mg/kg) and ALGX‐2542 (10mg/kg) also inhibited mechanical allodynia in the SNL model with %MPE values of 38 to 65%. The effect of ALGX‐2542 (10mg/kg) was also evaluated in the paclitaxel chemotherapeutic‐induced neuropathic pain model and displayed similar efficacy in inhibiting mechanical hyperalgesia as observed in the SNL pain model. These results demonstrate Algomedix TRPA1 antagonists possess the requisite high potency, specificity, and pharmacokinetic properties to achieve substantial efficacy in multiple neuropathic pain models and hold promise as a new class of analgesic drugs for effectively and safely treating neuropathic pain patients. Support or Funding Information Supported by NIH grants 1R43DA031516 and 1R43AR065330 (JMH)

Pharmacologically Inhibiting Glur2 Internalization Alleviates Neuropathic Pain

A Synthetic Peptide Disturbing GluN2A/SHP1 Interaction in Dorsal Root Ganglion Attenuated Pathological Pain

Glur2-3y Inhibits the Acquisition and Reinstatement of Morphine-Induced Conditioned Place Preference in Rats

Intrathecal delivery of a palmitoylated peptide targeting Y382-384 within the P2X7 receptor alleviates neuropathic pain

Enduring Reversal of Neuropathic Pain by a Single Intrathecal Injection of Adenosine 2A Receptor Agonists: A Novel Therapy for Neuropathic Pain

MrgC Agonism at Central Terminals of Primary Sensory Neurons Inhibits Neuropathic Pain

Intravenous Injection of GluR2-3Y Inhibits Repeated Morphine-Primed Reinstatement of Drug Seeking in Rats

Pharmacological Inhibition of CXCR2 Alleviates Neuropathic Pain by Inactivating Microglia in a Rat L5 Spinal Nerve Ligation Model.

Evaluation of the Effect of (S)-3,4-Dicarboxyphenylglycine as a Metabotropic Glutamate Receptors Subtype 8 Agonist on Thermal Nociception Following Central Neuropathic Pain

Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain

Antinociceptive synergistic effect of spinal mGluR2/3 antagonist and glial cells inhibitor on peripheral inflammation-induced mechanical hypersensitivity.

Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice

A Synthetic Cell-Penetrating Peptide Antagonizing Trka Function Suppresses Neuropathic Pain in Mice

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain

N-methyl D-aspartate Receptor Subtype 2B Antagonist, Ro 25-6981, Attenuates Neuropathic Pain by Inhibiting Postsynaptic Density 95 Expression

A Role of Periaqueductal Grey NR2B-Containing NMDA Receptor in Mediating Persistent Inflammatory Pain

An Anti-Nociceptive Role for Ceftriaxone in Chronic Neuropathic Pain in Rats

Vegf and Its Receptor-2 Involved in Neuropathic Pain Transmission Mediated by P2x(2/3) Receptor of Primary Sensory Neurons

Activation of the Intrinsic Pain Inhibitory Circuit from the Midcingulate Cg2 to Zona Incerta Alleviates Neuropathic Pain

A Novel Class of Potent, Allosteric Trpa1 Antagonists Reverse Hyperalgesia in Multiple Rat Models of Neuropathic Pain

TFAP2A is involved in neuropathic pain by regulating Grin1 expression in glial cells of the dorsal root ganglion